Market capitalization | $111.93m |
Enterprise Value | $-55.86m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | 0.67 |
P/B ratio (TTM) P/B ratio | 0.64 |
Revenue (TTM) Revenue | $0.00 |
EBIT (operating result TTM) EBIT | $-114.50m |
Free Cash Flow (TTM) Free Cash Flow | $-83.57m |
Cash position | $183.01m |
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
12 Analysts have issued a Cabaletta Bio Inc forecast:
12 Analysts have issued a Cabaletta Bio Inc forecast:
Sep '24 |
+/-
%
|
||
Revenue | - - |
-
|
|
Gross Profit | -1.58 -1.58 |
68%
68%
|
|
EBITDA | -113 -113 |
79%
79%
|
EBIT (Operating Income) EBIT | -115 -115 |
69%
69%
|
Net Profit | -104 -104 |
67%
67%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Cabaletta Bio, Inc. operates as a clinical-stage biotechnology company, which engages in the discovery and development of engineered T cell therapies for B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor to selectively bind and eliminate B cells that produce disease-causing autoantibodies. The company was founded by Michael C. Milone, Steven Nichtberger, and Aimee Payne in April 2017 and is headquartered in Philadelphia, PA.
Head office | United States |
CEO | Steven Nichtberger |
Employees | 103 |
Founded | 2017 |
Website | www.cabalettabio.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.